Kenvue (NYSE:KVUE) Given New $25.00 Price Target at JPMorgan Chase & Co.

Kenvue (NYSE:KVUE - Get Free Report) had its price target lifted by equities researchers at JPMorgan Chase & Co. from $24.00 to $25.00 in a note issued to investors on Friday, Benzinga reports. The brokerage presently has an "overweight" rating on the stock. JPMorgan Chase & Co.'s price target points to a potential upside of 16.50% from the stock's current price.

A number of other research analysts have also recently commented on KVUE. Deutsche Bank Aktiengesellschaft increased their target price on Kenvue from $23.00 to $24.00 and gave the company a "buy" rating in a research note on Wednesday, August 7th. Royal Bank of Canada lowered Kenvue from an "outperform" rating to a "sector perform" rating and set a $24.00 price objective on the stock. in a research report on Tuesday, September 24th. Jefferies Financial Group initiated coverage on Kenvue in a research note on Tuesday, September 24th. They issued a "buy" rating and a $27.00 target price for the company. Citigroup decreased their price target on shares of Kenvue from $21.00 to $20.00 and set a "neutral" rating on the stock in a research note on Wednesday, July 10th. Finally, Piper Sandler upped their price objective on shares of Kenvue from $20.00 to $21.00 and gave the company a "neutral" rating in a research note on Monday, September 23rd. One research analyst has rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $22.20.

Kenvue Price Performance

NYSE KVUE traded up $0.14 during trading on Friday, reaching $21.46. The company's stock had a trading volume of 14,513,021 shares, compared to its average volume of 18,237,896. The firm has a fifty day moving average of $22.08 and a 200 day moving average of $20.19. Kenvue has a one year low of $17.67 and a one year high of $23.55. The stock has a market capitalization of $41.10 billion, a PE ratio of 37.00, a P/E/G ratio of 2.76 and a beta of 1.40. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.99 and a quick ratio of 0.68.

Kenvue (NYSE:KVUE - Get Free Report) last announced its earnings results on Tuesday, August 6th. The company reported $0.32 earnings per share for the quarter, beating analysts' consensus estimates of $0.28 by $0.04. Kenvue had a net margin of 7.23% and a return on equity of 21.80%. The business had revenue of $4 billion for the quarter, compared to the consensus estimate of $3.93 billion. During the same period last year, the firm posted $0.32 earnings per share. Kenvue's quarterly revenue was down .3% on a year-over-year basis. Analysts expect that Kenvue will post 1.08 EPS for the current fiscal year.

Hedge Funds Weigh In On Kenvue

A number of hedge funds have recently modified their holdings of KVUE. Manchester Capital Management LLC increased its holdings in Kenvue by 80.8% during the 1st quarter. Manchester Capital Management LLC now owns 1,186 shares of the company's stock valued at $25,000 after purchasing an additional 530 shares during the period. Mather Group LLC. bought a new position in shares of Kenvue during the first quarter valued at approximately $28,000. MV Capital Management Inc. raised its holdings in shares of Kenvue by 71.2% during the first quarter. MV Capital Management Inc. now owns 1,544 shares of the company's stock valued at $33,000 after acquiring an additional 642 shares in the last quarter. Salomon & Ludwin LLC purchased a new stake in Kenvue in the first quarter worth $33,000. Finally, Riverview Trust Co bought a new stake in Kenvue in the first quarter valued at $33,000. Hedge funds and other institutional investors own 97.64% of the company's stock.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.